NEW YORK (TheStreet) -- On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, was very excited about Regeneron's (REGN - Get Report) new cholesterol drug, Alirocumab.
The stock is breaking out, Cramer said, adding that Credit Suisse suggests it can go to $400 per share.
"It's a very big win for Regeneron. It could be a multi-billion market," he said.
Investors want exposure to domestic retailers to protect themselves from geopolitical risks, Cramer said, but not all domestic retailers are created equal.
He concluded that he is not a buyer of Conn's following the selloff, because a lot of investors still want to get out of the stock.
-- Written by Bret Kenwell in Petoskey, Mich.